💰 Dividend History

No dividend history available.

📅 Earnings & EPS History for OIM

No earnings history available for this symbol.

📰 Related News & Research

• Dianthus Therapeutics Advances Claseprubart and DNTH212 as Potential Best-in-Class Autoimmune Therapies with Pipeline-in-a-Product Potential and Strong Clinical Data
  March 26, 2026
  

  Dianthus Therapeutics Investor Update: Advancing Autoimmune ...

• Nkarta, Inc. 2025 Annual Report: Advancing Allogeneic CAR NK-Cell Therapies for Cancer and Autoimmune Diseases
  March 26, 2026
  

  Nkarta, Inc. 2025 Annual Report: Key Insights for Investors ...

• Equillium 2025 10-K: Advancing EQ504 AhR Modulator for Autoimmune & Inflammatory Disease Therapies
  March 26, 2026
  

  Equillium, Inc. 2025 Annual Report: Investor Analysis ...

• Aurinia Pharmaceuticals Announces New CEO and Leadership Team Amid Continued Growth in Autoimmune Disease Therapies 1
  March 23, 2026
  

  Aurinia Pharmaceuticals Announces Major Management Changes a...

• Cabaletta Bio 2024 Annual Report: Engineered T Cell Therapies, Competitive Landscape, and Intellectual Property Strategies for Autoimmune Diseases
  March 23, 2026
  

  Cabaletta Bio, Inc. 2025 Annual Report: Key Investor Highlig...

• Zura Bio Limited 2025 Annual Report: Clinical-Stage Biotech Advancing Novel Autoimmune Therapies and Key Risk Factors
  March 20, 2026
  

  Zura Bio Limited 2025 Annual Report: Key Insights for Invest...

• Estrella Immunopharma: Advancing Next-Generation T-Cell Therapies for Cancer and Autoimmune Diseases
  March 18, 2026
  

  Estrella Immunopharma, Inc. 2025 Annual Report: Key Investor...

• Coya Therapeutics: Advancing Treg-Based Therapies for Neurodegenerative and Autoimmune Diseases
  March 16, 2026
  

  Coya Therapeutics, Inc. 2025 Annual Report – Investor Summar...

• Adicet Bio Reports Strong 2025 Financial Results and Advances Key Autoimmune and Cancer Cell Therapy Programs
  March 13, 2026
  

  Adicet Bio Reports Q4 and Full-Year 2025 Financial Results: ...

• Allogene Therapeutics 2025 Annual Report: Advancing Allogeneic CAR T Cell Therapies for Cancer and Autoimmune Diseases
  March 13, 2026
  

  Allogene Therapeutics, Inc. 2025 Annual Report – Key Financi...

🔍 View more Reports